Assessment of disease activity in muscular dystrophies by noninvasive imaging

Journal of Clinical Investigation

Volumn 123, Issue 5, 2013, Pages 2298-2305

  Maguire, Katie K ^a   Lim, Leland ^b   Speedy, Sedona ^a   Rando, Thomas A ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSFERLIN; LIMB GIRDLE MUSCULAR DYSTROPHY 2B PROTEIN; LUCIFERASE; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CELL ACTIVATION; CELL PROLIFERATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DISEASE COURSE; GENE MUTATION; HISTOPATHOLOGY; MEDICAL HISTORY; MOUSE; MUSCLE ATROPHY; MUSCLE STEM CELL; MUSCULAR DYSTROPHY; NON INVASIVE PROCEDURE; NONHUMAN; NONINVASIVE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; STEM CELL;

ANIMALS; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; FEMALE; GENES, REPORTER; IMAGE PROCESSING, COMPUTER-ASSISTED; LUCIFERASES; LUMINESCENT MEASUREMENTS; MALE; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; MUSCLE, SKELETAL; MUSCLES; MUSCULAR DYSTROPHIES; PAX7 TRANSCRIPTION FACTOR; STEM CELLS;

EID: 84877117215     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI68458     Document Type: Article

References (34)

1. Cohn RD, Campbell KP. Molecular basis of muscular dystrophies. Muscle Nerve. 2000;23(10):1456-1471.
2. Goyenvalle A, Seto JT, Davies KE, Chamberlain J. Therapeutic approaches to muscular dystrophy. Hum Mol Genet. 2011;20(R1):R69-R78.
3. Vainzof M, et al. Animal models for genetic neuro-muscular diseases. J Mol Neurosci. 2008;34(3):241-248.
4. Lieberman JS, Taylor RG, Fowler WM. Serum creatine phosphokinase variations in dystrophic mice. Exp Neurol. 1981;73(3):716-724.
5. Dellorusso C, Crawford RW, Chamberlain JS, Brooks SV. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J Muscle Res Cell Motil. 2001;22(5):467-475.
6. McIntosh LM, Baker RE, Anderson JE. Magnetic resonance imaging of regenerating and dystrophic mouse muscle. Biochem Cell Biol. 1998;76(2-3):532-541.
7. Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P, Rudnicki MA. Pax7 is required for the specification of myogenic satellite cells. Cell. 2000;102(6):777-786.
8. Buckingham M, et al. Myogenic progenitor cells in the mouse embryo are marked by the expression of Pax3/7 genes that regulate their survival and myogenic potential. Anat Embryol (Berl). 2006;211(suppl 1):51-56.
9. Brack AS, et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science. 2007;317(5839):807-810.
10. Nishijo K, et al. Biomarker system for studying muscle, stem cells, and cancer in vivo. FASEB J. 2009;23(8):2681-2690.
11. Quach NL, Biressi S, Reichardt LF, Keller C, Rando TA. Focal adhesion kinase signaling regulates the expression of caveolin 3 and beta1 integrin, genes essential for normal myoblast fusion. Mol Biol Cell. 2009;20(14):3422- 3435.
12. Bjornson CR, Cheung TH, Liu L, Tripathi PV, Steeper KM, Rando TA. Notch signaling is necessary to maintain quiescence in adult muscle stem cells. Stem Cells. 2012;30(2):232-242.
13. Amato AA, Brown RH. Dysferlinopathies. Handb Clin Neurol. 2011;101:111-118.
14. Ho M, et al. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet. 2004; 13(18):1999-2010.
15. Bansal D, et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature. 2003;423(6936):168-172.
16. Bittner RE, et al. Dysferlin deletion in SJL mice (SJLDysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet. 1999;23(2):141-142.
17. Weller AH, Magliato SA, Bell KP, Rosenberg NL. Spontaneous myopathy in the SJL/J mouse: pathology and strength loss. Muscle Nerve. 1997;20(1):72-82.
18. Nemoto H, Konno S, Nakazora H, Miura H, Kurihara T. Histological and immunohistological changes of the skeletal muscles in older SJL/J mice. Eur Neurol. 2007;57(1):19-25.
19. Kobayashi K, Izawa T, Kuwamura M, Yamate J. The distribution and characterization of skeletal muscle lesions in dysferlin-deficient SJL and A/J mice. Exp Toxicol Pathol. 2010;62(5):509-517.
20. Wallace GQ, McNally EM. Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. Annu Rev Physiol. 2009;71:37-57.
21. Bushby KM. Dysferlin and muscular dystrophy. Acta Neurol Belg. 2000;100(3):142-145.
22. Reznik M, Engel WK. Ultrastructural and histochemical correlations of experimental muscle regeneration. J Neurol Sci. 1970;11(2):167-185.
23. Lepper C, Fan CM. Inducible lineage tracing of Pax7-descendant cells reveals embryonic origin of adult satellite cells. Genesis. 2010;48(7):424-436.
24. Schultz E. Satellite cell proliferative compartments in growing skeletal muscles. Dev Biol. 1996;175(1):84-94.
25. White RB, Bierinx AS, Gnocchi VF, Zammit PS. Dynamics of muscle fibre growth during postnatal mouse development. BMC Dev Biol. 2010;10:21.
26. Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A. 1984; 81(4):1189-1192.
27. Dangain J, Vrbova G. Muscle development in mdx mutant mice. Muscle Nerve. 1984;7(9):700-704.
28. DiMario JX, Uzman A, Strohman RC. Fiber regeneration is not persistent in dystrophic (MDX) mouse skeletal muscle. Dev Biol. 1991;148(1):314-321.
29. Suzuki N, et al. Continuous administration of poloxamer 188 reduces overload-induced muscular atrophy in dysferlin-deficient SJL mice. Neurosci Res. 2012;72(2):181-186.
30. Nemoto H, et al. Anti-TNF therapy using etanercept suppresses degenerative and inflammatory changes in skeletal muscle of older SJL/J mice. Exp Mol Pathol. 2011;90(3):264-270.
31. Rayavarapu S, Van der Meulen JH, Gordish-Dressman H, Hoffman EP, Nagaraju K, Knoblach SM. Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype. PLoS One. 2010;5(9):e12981.
32. Paradas C, et al. Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Neurology. 2010;75(4):316-323.
33. Gayathri N, et al. Dysferlinopathy: spectrum of pathological changes in skeletal muscle tissue. Indian J Pathol Microbiol. 2011;54(2):350-354.
34. Schmidt S, et al. Dysferlin-deficient muscular dystrophy: gadofluorine M suitability at MR imaging in a mouse model. Radiology. 2009;250(1):87-94.